Arbutus Biopharma Corp

ABUSReported to SECin USCIK 0001447028Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 20. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 20
Form 4 lines at Arbutus Biopharma Corp, most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Androski LindsayPresident and CEOOption exercisenothing paid10,456 sharesSep 23, 2026Androski LindsayPresident and CEOnothing paidExercise · Sep 23Option exercise10,456Sep 23, 2026
Androski LindsayPresident and CEOOption exercisenothing paid116,408 sharesSep 23, 2026Androski LindsayPresident and CEOnothing paidExercise · Sep 23Option exercise116,408Sep 23, 2026
Androski LindsayPresident and CEOAdministrative$418,41282,527 sharesSep 23, 2026Androski LindsayPresident and CEO$418,412Admin · Sep 23Administrative82,527Sep 23, 2026
Androski LindsayPresident and CEOOption exercise$45,90210,456 sharesSep 23, 2026Androski LindsayPresident and CEO$45,902Exercise · Sep 23Option exercise10,456Sep 23, 2026
Androski LindsayPresident and CEOOption exercise$372,506116,408 sharesSep 23, 2026Androski LindsayPresident and CEO$372,506Exercise · Sep 23Option exercise116,408Sep 23, 2026